REG - Cambridge Cognition - £1.0m Schizophrenia clinical trial contract

Cambridge Cognition HoldingsAnnouncement

09/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211209:nRSI0511Va&default-theme=true

RNS Number : 0511V  Cambridge Cognition Holdings PLC  09 December 2021

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition wins £1.0m schizophrenia clinical trial contract

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that it has
secured a contract for an additional schizophrenia clinical trial worth
£1.0m.  The revenue from this contract is expected over the next three
years.  Cambridge Cognition will provide proprietary cognitive assessments
(CANTAB(TM)) and specialist, study management services.  This contract is a
repeat purchase from an existing client that has contracted for several other
clinical trials for schizophrenia.

 

Cognitive impairment is a core feature of schizophrenia, with deficits
frequently observed in memory, attention and executive functions.  Cambridge
Cognition has secured these contracts on the strength of the Company's
reputation for quality service and its cognitive assessments (CANTAB(TM))
capable of measuring the distinct cognitive processes compromised in
schizophrenia.

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are delighted to have formed an enduring partnership with this
pharmaceutical company that recognises the potential for our sensitive
cognitive assessments to be used in pivotal clinical trials.  This continues
to be an exciting area for potential further growth for the Company in the
future."

 

For further information, contact:

 

 Cambridge Cognition Holdings Plc             Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer       press@camcog.com (mailto:press@camcog.com)

 Nick Walters, Chief Financial Officer
 finnCap Ltd (NOMAD and Joint Broker)         Tel: 020 7220 0500

 Geoff Nash / Simon Hicks                     (Corporate Finance)

 Alice Lane / Charlotte Sutcliffe             (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)       Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)       Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTFFFLLFSLTIIL